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It is shown that adriamycin is able to chelate iron released from iron-loaded serum transferrin in the pH 
range from 6.54.1. The kinetics of iron transfer to free adriamycin and to adriamycin covalently attached 
to the transferrin has been determined. The results show that adriamycin, if introduced into intracellular 
acidic compa~ments, could function as acceptor for transferrin-iron. 
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1. INTRODUCTION 
Adriamycin (doxorubicin), an anthracycline an- 
tibiotic with antitumor activity, interacts with Fe3+ 
forming complexes of considerable stability (1,2]. 
There is evidence from several in vitro studies 
[3-l I] that these drug-metal ion complexes can act 
as redox catalysts in the formation of reactive and 
toxic oxygen species. In a previous report [12] we 
showed that ADM in vitro is capable of binding 
iron from the iron storage protein ferritin. We 
have extended this work to the interaction between 
ADM and the serum glycoprotein Tr involved in 
iron transport. 
2. MATERIALS AND METHODS 
2.1. preparation of iron-loaded transferri~ 
Iron-loading of human serum transferrin 
carried out with ferric nitrilotriacetate in 
presence of carbonate [ 131. Nitrilotriacetate 
was 
the 
and 
excess iron was removed by passage of Fe-Tr 
through a 25 x 2.5 cm Sephadex G-25 column 
equilibrated and eluted with 0.1 M NaCl04 [13, 
141, followed by dialysis at 4°C for 3 days against 
3 changes of 500 ml of 20 mM Hepes (pH 7.4). Fe- 
Abbreviations: ADM, adriamycin; Tr, transferrin; Fe- 
Tr, iron-loaded transferrin 
Tr concentration was determined at 280 nm using 
A!?,,, = 14.1 [15] and an M, for Tr of 79600 [16]. 
Total iron in Fe-Tr was determined after sulfuric 
acid digestion as described in [17]. The total iron 
content was 1.87 + 0.04 mol Fe/mol Tr (mean f: 
SE of 3 preparations). From the absorbance at 
465 nm [18] an iron content of 1.95 f 0.01 mol 
Fe/m01 Tr was calculated. 
2.2. Determination of iron transfer to ADM 
Formation of ADM-Fe’+ complex with Fe-Tr as 
iron donor was monitored spectrophotometrically 
using the appearance of an absorption band at 
600 nm for ADM upon binding to Fe’+ [5]. The 
reactions were performed in l-cm light-path cu- 
vettes thermostatted to 37 & 1°C and the reaction 
mixtures contained 500-550 pl of 150 mM NaCl, 
50 mM Tris-acetate buffer titrated with HCI to 
various pH values, O-30 pl of 5 mM ADM/HCl in 
water and 25-50 r(ll Fe-Tr or 100-I 50 yl ADM-(Fe- 
Tr) conjugate added as the last component. 
2.3. Materials 
Human serum transferrin (98%) substantially 
iron-free) and Nasnitrilotriacetate were from 
Sigma (St. Louis, MO). NazADP and Na2ATP 
were obtained from Boehringer (Mannheim) and 
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dithiobis(succinimidy1 propionate) from Pierce (Il- 
linois, USA). Adriamycin/HCl was a gift from 
Farmitalia Carlo Erba (Milano, Italy). 
3. RESULTS AND DISCUSSION 
Time courses for formation of 600 nm light- 
absorbing ADM-Fe3+ complex during incubation 
on ADM with Fe-Tr in KCI-Tris-acetate buffers at 
various pH values are given in fig.lA. Complex 
formation occurred at increasing rates when pH 
was lowered from 6.5 to 4.6. In the same pH 
range, iron dissociated from the iron binding sites 
of the Tr as judged by the disappearance of 
465 nm absorbance during incubation of Fe-Tr in 
the absence of ADM (fig. 1B). Formation of ADM- 
Fe3+ complex appeared to be transient at pH 
values below 4.6. Using 6 = 11400 M-‘*cm-’ for 
the (ADM)3-Fe3+ complex at 600 nm [5] and 6 = 
4800 M-i .crn-’ for diferric Tr at 465 nm [18] the 
initial rates for formation of ADM-Fe3+ complex 
at the different pH values were estimated to be 
about equal to or lower than the initial rates of loss 
of iron from Fe-Tr. Thus, the observed binding of 
Tr-iron by ADM can be explained by chelation of 
Fig. 1. (A) Time courses for formation of 600 nm absor- 
bance during incubation of iron-loaded transferrin with 
adriamycin. Transferrin (10.6 PM), adriamycin (69.4) 
,uM) and buffer-pH values as indicated. (B) Loss of iron 
from iron-loaded transferrin monitored at 465 nm dur- 
ing incubations in the absence of adriamycin. Transfer- 
Fig.2. Initial rates and plateau values (inset) for develop- 
ment of 600 nm absorbance during incubation of iron- 
loaded transferrin (10.6 PM) with adriamycin at dif- 
ferent concentrations (14.1-253 PM). Buffer pH (5.23- 
5.25). Data are presented as the mean f SE from 3 
rin (10.8 FM) and buffer-pH values as indicated. separate experiments. 
the iron which dissociates from the Tr at acidic 
pH. The finding that the initial rates for develop- 
ment of 600 nm absorbance were almost indepen- 
dent of ADM concentration when present in molar 
excess to Tr-iron is consistent with this mechanism 
(fig.2). The plateau values for 600 nm absorbance 
reached at the different ADM concentrations are 
given in the inset of fig.2. About 45% of the total 
iron in Fe-Tr was estimated to be complexed by 
ADM at 100,4M. 
The binding by ADM or iron released from Fe- 
Tr at acidic pH was inhibited by the iron chelators 
EDTA, nitrilotriacetate, phosphate and ATP 
whereas ADP appeared to facilitate iron transfer 
to ADM (table 1). ADP was also able to counteract 
the inhibitory effect of phosphate. The reason for 
this may be found in the ability of ADP to form 
stable ternary complexes with ADM and Fe3+ [3]. 
Ca2+ and Mg2+ had no significant effect on the 
kinetics of iron binding by ADM. 
The kinetics of iron transfer to ADM covalently 
attached to Fe-Tr was also determined. ADM was 
conjugated to Fe-Tr by linking the sugar amino 
group of ADM to amino groups in the protein with 
the bifunctional reagent dithiobis(succinimidy1 
propionate) [19] leaving the metal ion binding 
capacity of the anthracycline moiety of ADM in- 
tact (in preparation). The pH threshold for iron 
transfer to the protein-bound ADM was found 
similar to that for transfer to ‘free’ ADM 
(pH 5.5-5.6), but the rates of iron transfer ob- 
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Table 1 
Effect of various factors on the kinetics for binding of 
transferrin-iron by adriamycin 
Incubation system 
(5.30-5.38). Results are mean rl: SE, n=3-5 
Initial AA/min AA,,, 
ADM + Fe-Tr 0.027 f 0.003 0.108 f 0.017 
+ EDTA (0.2 mM) - 0.001 * 0.001 
f nitrilotriacetate 
(0.2 mM) 0.001 + 0.001 
+ phosphate 
(I mM) 0.020 * 0.011 0.011 * 0.002 
+ ATP (I mM) 0.018 + 0.004 0.020 * 0.002 
+ ADP (1 mM) 0.082 f 0.003 0.097 it 0.002 
+ ADP (1 mM) + 
phosphate (1 mM) 0.092 f 0.018 0.093 f 0.010 
+ Ca*+ (1 mM) 0.030 f 0.002 0.107 +_ 0.002 
+ Mg*+ (1 mM) 0.034 * 0.009 0.117 f 0.007 
Formation of adriamycin-Fe3+ complex was followed at 
600 nm during incubation at 37OC. Iron-loaded 
transferrin (17.5 pM), adriamycin (80.1 PM) and pH 
tained in the conjugates were 4-s-times slower 
than measured with ‘free’ ADM (fig.3). This may 
be due to the low diffusion coefficient of the 
protein-fixed ADM compared to that of ‘free’ 
ADM or to steric hindrance to iron binding by 
ADM on the surface of the protein. 
There is evidence both from microscopic and 
biochemical studies, that cells can obtain iron by 
receptor-mediated endocytosis of Fe-Tr [20]. The 
low affinity of Tr for iron at acidic pH [21,22] sug- 
gests that iron is released from the internalized 
receptor-(Fe-Tr) complex during its passage 
through acidic cell compartments 123,241. This 
study shows that ADM has the capacity for 
chelating iron which dissociates from Fe-Tr at 
acidic pH. The results therefore suggest that 
ADM, if introduced into Fe-Tr containing acidic 
compartments, could act as a ‘false’ acceptor for 
iron. ADM is a membrane permeable weak base 
and can be expected to concentrate in acidic cell 
structures by a simple diffusion process [25,26]. A 
recent study [27] indicates that iron is accessible to 
chelation by 2,2’-bipyridine and phenanthroline 
immediately after release from Fe-Tr in intra- 
cellular vesicles. It is clear, also from the data in 
table 1, that the efficiency of ADM as an acceptor 
for Tr-iron in cell organelles will depend on the 
properties and affinity of other potential iron 
Fig.3. Effect of pH on the initial rates of Fe3+ transfer 
from transferrin to free adriamycin (0) and to adria- 
(70.6-71.7 PM). 
mycin conjugated to transferrin (0). (0) Transferrin 
(5.30-5.34 /rM) and adriamycin (69.7 ,uM). (0) Trans- 
ferrin (5.1 l-5.20pM) and transferrin-bound adriamycin 
chelating agents present. The finding that ADM 
can exchange iron with Fe-Tr at acidic pH also 
after covalent attachment to Tr opens the possibili- 
ty for specific studies on intracellular iron chela- 
tion by ADM. Membrane_ binding and endocytosis 
of ADM-(Fe-Tr) conjugates are presently being in- 
vestigated. 
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